

Immunization Programs and Vaccine Preventable Diseases Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: April 8, 2024 Administrative Circular: 2024:07

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- Spring 2024 Booster Dose Recommendations were added. Individuals aged 65 years and older, Indigenous peoples aged 55 years and older, residents of long-term care/assisted living facilities or alternate level of care clients awaiting placement in LTC, and individuals 6 months of age and older who are moderately to severely immunosuppressed are recommended to receive an additional dose of COVID-19 XBB.1.5 vaccine 6 months following their last dose (with a minimum interval of 3 months). NOTE: Eligible individuals should receive the Spring 2024 Booster Dose before the end of June 2024 to support an adequate interval between doses for a potential Fall 2024 program.
- Individuals 6 months of age and older who have not received at least one dose of the COVID-19 XBB.1.5 formulation remain eligible for this dose. All individuals are recommended to have at least 1 dose of the COVID-19 XBB.1.5 vaccine.
- The "COVID-19 XBB.1.5 mRNA Vaccine Recommendations" table has been revised to include additional details regarding recommended doses based on COVID-19 XBB.1.5 vaccination history. Corresponding footnotes have been updated accordingly.
- Appendix C outlining individuals with underlying health conditions was removed.
- Moderately to severely immunosuppressed individuals 5 years of age and older who are initiating vaccination should receive 2 doses of COVID-19 XBB.1.5 vaccine. However, if any dose in the series is a non-XBB.1.5 COVID-19 vaccine, a total of at least 3 doses of COVID-19 vaccine is recommended with at least one of these doses provided as COVID-19 XBB.1.5 formulation. New recipients of HSCT or CART should receive 3 doses, regardless of formulation.

Please remove page numbers: 1-3 dated December 2023 Please add new page numbers: 1-3 dated April 2024

Page 1 of 5





COVID-19 mRNA Vaccine COMIRNATY® Omicron XBB.1.5 (Pfizer-BioNTech)

- DOSES AND SCHEDULE:
 - Additional details regarding recommended doses based on COVID-19 XBB.1.5 vaccination history have been added.
 - Spring 2024 Booster dose and schedule has been added.
 - Moderately to severely immunosuppressed individuals 5 years of age and older who are initiating vaccination should receive 2 doses of COVID-19 XBB.1.5 vaccine. However, if any dose in the series is a non-XBB.1.5 COVID-19 vaccine, a total of at least 3 doses of COVID-19 vaccine is recommended with at least one of these doses provided as COVID-19 XBB.1.5 formulation. New recipients of HSCT or CART should receive 3 doses, regardless of formulation.
- BOOSTER DOSES: Spring 2024 Booster Dose recommendations have been added.
- ADVERSE EVENTS: Additional content has been added regarding the decreased likelihood of myocarditis and/or pericarditis for individuals 12-29 years of age due to the use of a single dose schedule for most individuals in this age group and potentially due to a lower dosage of the available Moderna COVID-19 vaccine.

Please remove page numbers: 1-5 dated October 2023 Please add new page numbers: 1-5 dated April 2024

COVID-19 mRNA Vaccine COMIRNATY® Omicron XBB.1.5 (Pfizer-BioNTech) 5-11 Years of Age

- DOSES AND SCHEDULE:
 - Additional details regarding recommended doses based on COVID-19 XBB.1.5 vaccination history have been added.
 - o Spring 2024 Booster dose and schedule has been added.
 - Moderately to severely immunosuppressed individuals 5 years of age and older who are initiating vaccination should receive 2 doses of COVID-19 vaccine. However, if any dose in the series is a non-XBB.1.5 COVID-19 vaccine, a total of at least 3 doses of COVID-19 vaccine is recommended with at least one of these doses provided as COVID-19 XBB.1.5 formulation. New recipients of HSCT or CART should receive 3 doses, regardless of formulation.
- BOOSTER DOSES: Spring 2024 Booster Dose recommendations have been added.
- ADVERSE EVENTS: Additional content has been added regarding the decreased likelihood of myocarditis and/or pericarditis for individuals 12-29 years of age due to the use of a single dose schedule for most individuals in this age group and potentially due to a lower dosage of the available Moderna COVID-19 vaccine.

Please remove page numbers: 1-5 dated December 2023 Please add new page numbers: 1-5 dated April 2024





COVID-19 mRNA Vaccine COMIRNATY® Omicron XBB.1.5 (Pfizer-BioNTech) 6 months – 4 years of age

- DOSES AND SCHEDULE:
 - Additional details regarding recommended doses based on COVID-19 XBB.1.5 vaccination history have been added.
 - o Spring 2024 Booster dose and schedule has been added.
- BOOSTER DOSES: Spring 2024 Booster Dose recommendations have been added.
- ADVERSE EVENTS: Additional content has been added regarding the decreased likelihood of myocarditis and/or pericarditis for individuals 12-29 years of age due to the use of a single dose schedule for most individuals in this age group and potentially due to a lower dosage of the available Moderna COVID-19 vaccine.

Please remove page numbers: 1-5 dated October 2023 Please add new page numbers: 1-6 dated April 2024

COVID-19 mRNA Vaccine SPIKEVAX® XBB.1.5 (Moderna)

- DOSES AND SCHEDULE:
 - Additional details regarding recommended doses based on COVID-19 XBB.1.5 vaccination history have been added.
 - Spring 2024 Booster dose and schedule has been added.
 - Recommendations for moderately to severely immunosuppressed individuals are now presented in two tables according to age.
 - Moderately to severely immunosuppressed individuals 5 years of age and older who are initiating vaccination should receive 2 doses of COVID-19 XBB.1.5 vaccine. However, if any dose in the series is a non-XBB.1.5 COVID-19 vaccine, a total of at least 3 doses of COVID-19 vaccine is recommended with at least one of these doses provided as COVID-19 XBB.1.5 formulation. New recipients of HSCT or CART should receive 3 doses, regardless of formulation.
- BOOSTER DOSES: Spring 2024 Booster Dose recommendations have been added.
- ADVERSE EVENTS: Additional content has been added regarding the decreased likelihood of myocarditis and/or pericarditis for individuals 12-29 years of age due to the use of a single dose schedule for most individuals in this age group and potentially due to a lower dosage of the available Moderna COVID-19 vaccine.

Please remove page numbers: 1-4 dated October 2023 Please add new page numbers: 1-5 dated April 2024





COVID-19 Vaccine Nuvaxovid™ XBB.1.5 (Novavax)

- DOSES AND SCHEDULE:
 - The two-dose recommendation for unvaccinated immunocompetent individuals has been removed as only a single dose is recommended per NACI.
 - Additional details regarding recommended doses based on COVID-19 XBB.1.5 vaccination history have been added.
 - Moderately to severely immunosuppressed individuals 12 years of age and older who are initiating vaccination should receive 2 doses of COVID-19 XBB.1.5 vaccine. However, if any dose in the series is a non-XBB.1.5 COVID-19 vaccine, a total of at least 3 doses of COVID-19 vaccine is recommended with at least one of these doses provided as COVID-19 XBB.1.5 formulation. New recipients of HSCT or CART should receive 3 doses, regardless of formulation.
 - Spring 2024 Booster dose and schedule has been added.
- BOOSTER DOSES: Spring 2024 Booster Dose recommendations have been added.

Please remove page numbers: 1-3 dated December 22, 2023 Please add new page numbers: 1-4 dated April 2024





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Julene Cranch, Interim Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: julene.cranch@bccdc.ca)

Sincerely,

Jason Wong BMSc MD CCFP MPH FRCPC

Chief Medical Officer

BC Centre for Disease Control

pc:

Provincial Health Officer

Dr. Bonnie Henry

BC Ministry of Health, Communicable Disease Prevention and Control, Population & Public Health Division:

Bethany McMullen Director, Immunizations

Brian Sagar Executive Director



